EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases

Arjen Yousefi, Mark-David Levin, Jan J Cornelissen, Peter E Westerweel

Annals of Hematology · 2025

DOI: 10.1007/s00277-024-06170-4 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Arjen Yousefi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of internal medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selected chronic myeloid leukemia (CML) patients may discontinue their tyrosine kinase inihibitor (TKI) in an attempt to achieve sustained treatment-free remission (TFR), which mitigates therapy-related side effects and limits treatment costs. TFR has been extensively studied following the discontinuation of adenosine triphosphate (ATP) – competitive TKI. However, there is minimal data concerning TFR after the discontinuation of the novel TKI asciminib. Here, we present two CML patients intolerant to multiple ATP-competitive TKIs who achieved a deep molecular response (DMR) during asciminib treatment and sustained this remission after asciminib discontinuation. One of the cases developed transient myalgia and arthralgia after asciminib discontinuation consistent with a TKI withdrawal syndrome. Both patients have been free of molecular relapse for more than at least 8 months after TKI discontinuation without increase in molecular BCR::ABL1 signal. These two cases provide proof of principle that sustained TFR after discontinuing asciminib in CML patients is feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsPyrazolesHumansFusion Proteins, bcr-ablRemission InductionNiacinamide

Stichwörter der Autor:innen

AsciminibChronic myeloid leukemiaTKI withdrawal syndromeTreatment-free remission

Substanzen

Antineoplastic AgentsasciminibFusion Proteins, bcr-ablProtein Kinase InhibitorsPyrazolesNiacinamide

Autor:innen und Institutionen

  • Department of internal medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Department of hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of internal medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. p.e.westerweel@asz.nl.

Zitieren

APA

Yousefi, A., Levin, M. D., Cornelissen, J. J., & Westerweel, P. E. (2025). Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases. Annals of Hematology. https://doi.org/10.1007/s00277-024-06170-4

Vancouver

Yousefi A, Levin MD, Cornelissen JJ, Westerweel PE. Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases. Annals of Hematology. 2025. doi:10.1007/s00277-024-06170-4

BibTeX
@article{Yousefi2025,
  author = {Yousefi, Arjen and Levin, Mark-David and Cornelissen, Jan J and Westerweel, Peter E},
  title = {Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-024-06170-4}
}
Kostenlos starten →